Hypoxia-Inducible Factors Regulate Tumorigenic Capacity of Glioma Stem Cells

Cancer Cell

Volumn 15, Issue 6, 2009, Pages 501-513

  Li, Zhizhong ^a   Bao, Shideng ^a,b   Wu, Qiulian ^a,b   Wang, Hui ^a   Eyler, Christine ^a   Sathornsumetee, Sith ^a   Shi, Qing ^a   Cao, Yiting ^a   Lathia, Justin ^a,b   McLendon, Roger E ^a   Hjelmeland, Anita B ^a,b   Rich, Jeremy N ^a,b  

^a DUKE UNIVERSITY MEDICAL CENTER   (United States)

^b LERNER RESEARCH INSTITUTE   (United States)

Author keywords

CELLCYCLE; STEMCELL

Indexed keywords

HYPOXIA INDUCIBLE FACTOR 2ALPHA;

ANIMAL EXPERIMENT; ANIMAL MODEL; ARTICLE; CARCINOGENESIS; CELL PROLIFERATION; CELL SURVIVAL; CONTROLLED STUDY; GENE EXPRESSION; GLIOBLASTOMA; GLIOMA; HUMAN; HUMAN CELL; IN VITRO STUDY; IN VIVO STUDY; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; STEM CELL;

EID: 65749106405     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.ccr.2009.03.018     Document Type: Article

References (63)

1. Bao S., Wu Q., McLendon R.E., Hao Y., Shi Q., Hjelmeland A.B., Dewhirst M.W., Bigner D.D., and Rich J.N. Glioma stem cells promote radioresistance by preferential activation of the DNA damage response. Nature 444 (2006) 756-760
2. Bao S., Wu Q., Sathornsumetee S., Hao Y., Li Z., Hjelmeland A.B., Shi Q., McLendon R.E., Bigner D.D., and Rich J.N. Stem cell-like glioma cells promote tumor angiogenesis through vascular endothelial growth factor. Cancer Res. 66 (2006) 7843-7848
3. Bao S., Wu Q., Li Z., Sathornsumetee S., Wang H., McLendon R.E., Hjelmeland A.B., and Rich J.N. Targeting cancer stem cells through L1CAM suppresses glioma growth. Cancer Res. 68 (2008) 6043-6048
4. Beier D., Hau P., Proescholdt M., Lohmeier A., Wischhusen J., Oefner P.J., Aigner L., Brawanski A., Bogdahn U., and Beier C.P. CD133(+) and CD133(-) glioblastoma-derived cancer stem cells show differential growth characteristics and molecular profiles. Cancer Ress 67 (2007) 4010-4015
5. Blazek E.R., Foutch J.L., and Maki G. Daoy medulloblastoma cells that express CD133 are radioresistant relative to CD133- cells, and the CD133+ sector is enlarged by hypoxia. Int. J. Radiat. Oncol. Biol. Phys. 67 (2007) 1-5
6. Calabrese C., Poppleton H., Kocak M., Hogg T.L., Fuller C., Hamner B., Oh E.Y., Gaber M.W., Finklestein D., Allen M., et al. A perivascular niche for brain tumor stem cells. Cancer Cell 11 (2007) 69-82
7. Cardenas-Navia L.I., Yu D., Braun R.D., Brizel D.M., Secomb T.W., and Dewhirst M.W. Tumor-dependent kinetics of partial pressure of oxygen fluctuations during air and oxygen breathing. Cancer Res. 64 (2004) 6010-6017
8. Chi J.T., Wang Z., Nuyten D.S., Rodriguez E.H., Schaner M.E., Salim A., Wang Y., Kristensen G.B., Helland A., Borresen-Dale A.L., et al. Gene expression programs in response to hypoxia: cell type specificity and prognostic significance in human cancers. PLoS Med. 3 (2006) e47
9. Christensen K., Schroder H.D., and Kristensen B.W. CD133 identifies perivascular niches in grade II-IV astrocytomas. J Neurooncol. 90 (2008) 157-170
10. Compernolle V., Brusselmans K., Acker T., Hoet P., Tjwa M., Beck H., Plaisance S., Dor Y., Keshet E., Lupu F., et al. Loss of HIF-2alpha and inhibition of VEGF impair fetal lung maturation, whereas treatment with VEGF prevents fatal respiratory distress in premature mice. Nat. Med. 8 (2002) 702-710
11. Covello K.L., Kehler J., Yu H., Gordan J.D., Arsham A.M., Hu C.J., Labosky P.A., Simon M.C., and Keith B. HIF-2alpha regulates Oct-4: effects of hypoxia on stem cell function, embryonic development, and tumor growth. Genes Dev. 20 (2006) 557-570
12. Danet G.H., Pan Y., Luongo J.L., Bonnet D.A., and Simon M.C. Expansion of human SCID-repopulating cells under hypoxic conditions. J. Clin. Invest. 112 (2003) 126-135
13. Ezashi T., Das P., and Roberts R.M. Low O2 tensions and the prevention of differentiation of hES cells. Proc. Natl. Acad. Sci. USA 102 (2005) 4783-4788
14. Galli R., Binda E., Orfanelli U., Cipelletti B., Gritti A., De Vitis S., Fiocco R., Foroni C., Dimeco F., and Vescovi A. Isolation and characterization of tumorigenic, stem-like neural precursors from human glioblastoma. Cancer Res. 64 (2004) 7011-7021
15. Gassmann M., Fandrey J., Bichet S., Wartenberg M., Marti H.H., Bauer C., Wenger R.H., and Acker H. Oxygen supply and oxygen-dependent gene expression in differentiating embryonic stem cells. Proc. Natl. Acad. Sci. USA 93 (1996) 2867-2872
16. Gilbertson R.J., and Rich J.N. Making a tumour's bed: GSCs and the vascular niche. Nat. Rev. Cancer 7 (2007) 733-736
17. Gordan J.D., Bertout J.A., Hu C.J., Diehl J.A., and Simon M.C. HIF-2alpha promotes hypoxic cell proliferation by enhancing c-myc transcriptional activity. Cancer Cell 11 (2007) 335-347
18. Hambardzumyan D., Squatrito M., and Holland E.C. Radiation resistance and stem-like cells in brain tumors. Cancer Cell 10 (2006) 454-456
19. Harris A.L. Hypoxia-a key regulatory factor in tumour growth. Nat. Rev. Cancer 2 (2002) 38-47
20. Hemmati H.D., Nakano I., Lazareff J.A., Masterman-Smith M., Geschwind D.H., Bronner-Fraser M., and Kornblum H.I. Cancerous stem cells can arise from pediatric brain tumors. Proc. Natl. Acad. Sci. USA 100 (2003) 15178-15183
21. Holmquist-Mengelbier L., Fredlund E., Lofstedt T., Noguera R., Navarro S., Nilsson H., Pietras A., Vallon-Christersson J., Borg A., Gradin K., et al. Recruitment of HIF-1alpha and HIF-2alpha to common target genes is differentially regulated in neuroblastoma: HIF-2alpha promotes an aggressive phenotype. Cancer Cell 10 (2006) 413-423
22. Hu C.J., Iyer S., Sataur A., Covello K.L., Chodosh L.A., and Simon M.C. Differential regulation of the transcriptional activities of hypoxia-inducible factor 1 alpha (HIF-1alpha) and HIF-2alpha in stem cells. Mol. Cell. Biol. 26 (2006) 3514-3526
23. Hu T., Liu S., Breiter D.R., Wang F., Tang Y., and Sun S. Octamer 4 small interfering RNA results in cancer stem cell-like cell apoptosis. Cancer Res. 68 (2008) 6533-6540
24. Inoue S., and Ohnuma T. Effects of physiological oxygen environment on drug-induced cell lethality of multicellular tumor spheroids from human lung cancer. Sel. Cancer Ther. 5 (1989) 13-22
25. Jain R.K., di Tomaso E., Duda D.G., Loeffler J.S., Sorensen A.G., and Batchelor T.T. Angiogenesis in brain tumours. Nat. Rev. Neurosci. 8 (2007) 610-622
26. Jin L., Hope K.J., Zhai Q., Smadja-Joffe F., and Dick J.E. Targeting of CD44 eradicates human acute myeloid leukemic stem cells. Nat. Med. 12 (2006) 1167-1174
27. Kaur B., Khwaja F.W., Severson E.A., Matheny S.L., Brat D.J., and Van Meir E.G. Hypoxia and the hypoxia-inducible-factor pathway in glioma growth and angiogenesis. Neuro-oncol. 7 (2005) 134-153
28. Keith B., and Simon M.C. Hypoxia-inducible factors, stem cells, and cancer. Cell 129 (2007) 465-472
29. Kiel M.J., and Morrison S.J. Uncertainty in the niches that maintain haematopoietic stem cells. Nat. Rev. Immunol. 8 (2008) 290-301
30. Kimura H., Braun R.D., Ong E.T., Hsu R., Secomb T.W., Papahadjopoulos D., Hong K., and Dewhirst M.W. Fluctuations in red cell flux in tumor microvessels can lead to transient hypoxia and reoxygenation in tumor parenchyma. Cancer Res. 56 (1996) 5522-5528
31. Li X., Lewis M.T., Huang J., Gutierrez C., Osborne C.K., Wu M.F., Hilsenbeck S.G., Pavlick A., Zhang X., Chamness G.C., et al. Intrinsic resistance of tumorigenic breast cancer cells to chemotherapy. J. Natl. Cancer Inst. 100 (2008) 672-679
32. Liang B.C. Effects of hypoxia on drug resistance phenotype and genotype in human glioma cell lines. J. Neurooncol. 29 (1996) 149-155
33. Ligon K.L., Huillard E., Mehta S., Kesari S., Liu H., Alberta J.A., Bachoo R.M., Kane M., Louis D.N., Depinho R.A., et al. Olig2-regulated lineage-restricted pathway controls replication competence in neural stem cells and malignant glioma. Neuron 53 (2007) 503-517
34. Liu G., Yuan X., Zeng Z., Tunici P., Ng H., Abdulkadir I.R., Lu L., Irvin D., Black K.L., and Yu J.S. Analysis of gene expression and chemoresistance of CD133+ cancer stem cells in glioblastoma. Mol. Cancer 5 (2006) 67
35. Macheda M.L., Rogers S., and Best J.D. Molecular and cellular regulation of glucose transporter (GLUT) proteins in cancer. J. Cell. Physiol. 202 (2005) 654-662
36. Pan G.J., Chang Z.Y., Scholer H.R., and Pei D. Stem cell pluripotency and transcription factor Oct4. Cell Res. 12 (2002) 321-329
37. Parmar K., Mauch P., Vergilio J.A., Sackstein R., and Down J.D. Distribution of hematopoietic stem cells in the bone marrow according to regional hypoxia. Proc. Natl. Acad. Sci. USA 104 (2007) 5431-5436
38. Plate K.H., Breier G., Weich H.A., and Risau W. Vascular endothelial growth factor is a potential tumour angiogenesis factor in human gliomas in vivo. Nature 359 (1992) 845-848
39. Platet N., Liu S.Y., Atifi M.E., Oliver L., Vallette F.M., Berger F., and Wion D. Influence of oxygen tension on CD133 phenotype in human glioma cell cultures. Cancer Lett. 258 (2007) 286-290
40. Pouyssegur J., Dayan F., and Mazure N.M. Hypoxia signalling in cancer and approaches to enforce tumour regression. Nature 441 (2006) 437-443
41. Quintana E., Shackleton M., Sabel M.S., Fullen D.R., Johnson T.M., and Morrison S.J. Efficient tumour formation by single human melanoma cells. Nature 456 (2008) 593-598
42. Raval R.R., Lau K.W., Tran M.G., Sowter H.M., Mandriota S.J., Li J.L., Pugh C.W., Maxwell P.H., Harris A.L., and Ratcliffe P.J. Contrasting properties of hypoxia-inducible factor 1 (HIF-1) and HIF-2 in von Hippel-Lindau-associated renal cell carcinoma. Mol. Cell. Biol. 25 (2005) 5675-5686
43. Reya T., Morrison S.J., Clarke M.F., and Weissman I.L. Stem cells, cancer, and cancer stem cells. Nature 414 (2001) 105-111
44. Sathornsumetee S., Cao Y., Marcello J.E., Herndon II J.E., McLendon R.E., Desjardins A., Friedman H.S., Dewhirst M.W., Vredenburgh J.J., and Rich J.N. Tumor angiogenic and hypoxic profiles predict radiographic response and survival in malignant astrocytoma patients treated with bevacizumab and irinotecan. J. Clin. Oncol. 26 (2008) 271-278
45. Semenza G.L. Intratumoral hypoxia, radiation resistance, and HIF-1. Cancer Cell 5 (2004) 405-406
46. Singh S.K., Clarke I.D., Terasaki M., Bonn V.E., Hawkins C., Squire J., and Dirks P.B. Identification of a cancer stem cell in human brain tumors. Cancer Res. 63 (2003) 5821-5828
47. Singh S.K., Hawkins C., Clarke I.D., Squire J.A., Bayani J., Hide T., Henkelman R.M., Cusimano M.D., and Dirks P.B. Identification of human brain tumour initiating cells. Nature 432 (2004) 396-401
48. Tang W., Zeve D., Suh J.M., Bosnakovski D., Kyba M., Hammer R.E., Tallquist M.D., and Graff J.M. White fat progenitor cells reside in the adipose vasculature. Science 322 (2008) 583-586
49. Teicher B.A. Hypoxia and drug resistance. Cancer Metastasis Rev. 13 (1994) 139-168
50. Todaro M., Alea M.P., Di Stefano A.B., Cammareri P., Vermeulen L., Iovino F., Tripodo C., Russo A., Gulotta G., Medema J.P., et al. Colon cancer stem cells dictate tumor growth and resist cell death by production of interleukin-4. Cell Stem Cell 1 (2007) 389-402
51. Tomita S., Ueno M., Sakamoto M., Kitahama Y., Ueki M., Maekawa N., Sakamoto H., Gassmann M., Kageyama R., Ueda N., et al. Defective brain development in mice lacking the Hif-1alpha gene in neural cells. Mol. Cell. Biol. 23 (2003) 6739-6749
52. Trapani J.A., and Sutton V.R. Granzyme B: pro-apoptotic, antiviral and antitumor functions. Curr. Opin. Immunol. 15 (2003) 533-543
53. van Houdt I.S., Oudejans J.J., van den Eertwegh A.J., Baars A., Vos W., Bladergroen B.A., Rimoldi D., Muris J.J., Hooijberg E., Gundy C.M., et al. Expression of the apoptosis inhibitor protease inhibitor 9 predicts clinical outcome in vaccinated patients with stage III and IV melanoma. Clin. Cancer Res. 11 (2005) 6400-6407
54. Vaupel P., and Mayer A. Hypoxia in cancer: significance and impact on clinical outcome. Cancer Metastasis Rev. 26 (2007) 225-239
55. Vescovi A.L., Galli R., and Reynolds B.A. Brain tumour stem cells. Nat. Rev. Cancer 6 (2006) 425-436
56. Wang G.L., and Semenza G.L. Desferrioxamine induces erythropoietin gene expression and hypoxia-inducible factor 1 DNA-binding activity: implications for models of hypoxia signal transduction. Blood 82 (1993) 3610-3615
57. Wang J., Rao S., Chu J., Shen X., Levasseur D.N., Theunissen T.W., and Orkin S.H. A protein interaction network for pluripotency of embryonic stem cells. Nature 444 (2006) 364-368
58. Wang J., Sakariassen P.Ø., Tsinkalovsky O., Immervoll H., Bøe S.O., Svendsen A., Prestegarden L., Røsland G., Thorsen F., Stuhr L., et al. CD133 negative glioma cells form tumors in nude rats and give rise to CD133 positive cells. Int. J. Cancer 122 (2008) 761-768
59. Wulf G.G., Wang R.Y., Kuehnle I., Weidner D., Marini F., Brenner M.K., Andreeff M., and Goodell M.A. A leukemic stem cell with intrinsic drug efflux capacity in acute myeloid leukemia. Blood 98 (2001) 1166-1173
60. Yoshida S., Sukeno M., and Nabeshima Y. A vasculature-associated niche for undifferentiated spermatogonia in the mouse testis. Science 317 (2007) 1722-1726
61. Younes M., Brown R.W., Mody D.R., Fernandez L., and Laucirica R. GLUT1 expression in human breast carcinoma: correlation with known prognostic markers. Anticancer Res. 15 (1995) 2895-2898
62. Young J.L., Sukhova G.K., Foster D., Kisiel W., Libby P., and Schonbeck U. The serpin proteinase inhibitor 9 is an endogenous inhibitor of interleukin 1beta-converting enzyme (caspase-1) activity in human vascular smooth muscle cells. J. Exp. Med. 191 (2000) 1535-1544
63. Zheng X., Shen G., Yang X., and Liu W. Most C6 cells are cancer stem cells: evidence from clonal and population analyses. Cancer Res. 67 (2007) 3691-3697